Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

  • STATUS
    Recruiting
  • End date
    Dec 13, 2021
  • participants needed
    20
  • sponsor
    The Cleveland Clinic
Updated on 13 February 2021
corticosteroids
immunosuppressant
topical corticosteroid
panuveitis
ocular inflammation
acute anterior uveitis
prednisolone acetate ophthalmic suspension
sarcoidosis
anterior uveitis

Summary

Treatment with ACTHAR Gel will result in a reduction of ocular inflammation in patients with active ocular sarcoidosis that requires systemic immunosuppressant therapy (hypothesis)

Description

The initial treatment of ocular sarcoidosis usually relies on a combination of topical glucocorticoids and oral glucocorticoids, both of which are associated with significant ocular and systemic toxicities. Steroid-sparing therapies are limited by variable and unpredictable efficacy, prolonged time until clinical response, medication intolerance, and difficulties obtaining payor approval. As a result, it is not uncommon that treating physicians must choose between excessive glucocorticoid toxicity versus poor control of ocular inflammation. Ongoing ocular inflammation, in turn, leads to eventual visual loss and occasionally blindness.

There is a need for a more reliable, expeditious therapy that can be used as an alternative to glucocorticoids in sarcoidosis uveitis. Adrenocorticotropic hormone, through activation of melanocortin receptors on leukocytes, can dampen immune responses through non-glucocorticoid dependent mechanisms. The proposed study will aim to define whether there is effectiveness for ACTHAR gel in these patients, delineate an effect dosing regimen, and provide information about the safety of this approach for moderate to severe ocular sarcoidosis.

ACTHAR is a 39-amino acid peptide natural form of adrenocorticotropin hormone (ACTH) that was initially approved in 1952 by the FDA. It has since been approved for 19 indications including respiratory sarcoidosis, multiple sclerosis, and infantile spasms.

Details
Condition Anterior uveitis, Panuveitis, Uveitis, Ocular Sarcoidosis, acute anterior uveitis
Treatment Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
Clinical Study IdentifierNCT02725177
SponsorThe Cleveland Clinic
Last Modified on13 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 99 yrs?
Gender: Male or Female
Do you have any of these conditions: Uveitis or Anterior uveitis or Panuveitis or Ocular Sarcoidosis?
Do you have any of these conditions: Anterior uveitis or Ocular Sarcoidosis or acute anterior uveitis or Uveitis or Panuveitis?
Do you have any of these conditions: Uveitis or acute anterior uveitis or Panuveitis or Ocular Sarcoidosis or Anterior uveitis?
Patient with sarcoidosis as defined by ATS/ERS/WASOG guidelines (American Thoracic Society/European Respiratory Society /World Association of Sarcoidosis and Other Granulomatous Diseases)
Any posterior, intermediate or panuveitis of sufficient severity to warrant therapy, in the opinion of the treating physician --OR-- Anterior uveitis requiring 4 or more daily applications of topical corticosteroids to maintain control of inflammation, or uncontrolled with topical therapy
Persistent disease activity (active uveitis) at the time of screening

Exclusion Criteria

Other cause for ocular inflammation
Uncontrolled diabetes, hypertension, or other contra-indication to increased dosage of glucocorticoids
Recent (less than 4 weeks) intra-ocular or intra-orbital steroid injection
Escalation of immunosuppressive medications between screening and initiation of the study medication
Severe extra-ocular sarcoidosis likely to require additional therapy (in the opinion of the investigator)
Administration of an investigational medication for sarcoidosis within 3 months, or 5 half-lives, whichever is longer
Have a history of any opportunistic infection within 6 months prior to screening
Have any history of malignancy, except fully resected cutaneous squamous cell cancer or cutaneous basal cell cancer, or cervical carcinoma in-situ with a minimum of 5 years period without recurrence
Severe other organ disease felt to be likely to lead to death within the next six months
Unable to follow the study protocol, including the requisite travel and follow-up ocular testing
Women of childbearing potential must be using adequate birth control measures (abstinence, hormonal contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) and must agree to continue such precautions, and not become pregnant or plan a pregnancy for 6 months after receiving their last treatment with study agent. Women of childbearing potential must test negative on a serum pregnancy test at screening
Breastfeeding women are excluded from participation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note